The inhibitory effect of VSIG3 on activated T- cells and its striking expression in colorectal, hepatocellular, and gastric carcinomas suggests that targeting the VSIG3/VISTA pathway is a promising innovative approach for cancer immunotherapy [97]. Here, IGSF11 is linked to cancer.